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Highlights
 Elevated maternal emotional distress symptoms during pregnancy are associated with 
changes in placental genes regulating fetal glucocorticoid exposure and placental 
growth
 Although severely obese women have increased emotional distress symptoms
compared to normal-weight our findings suggest a protective adaptive responses from 
excess glucocorticoid exposure in the placentas of severely obese pregnancy
 The observed changes in placental gene expression suggest female fetuses are more 
vulnerable to maternal distress than males with potentially greater fetal glucocorticoid 
exposure and excess IGF2
 Further studies are needed to understand the placental adaptive changes to maternal 
distress in obese pregnancy and whether thee findings translate to potentially greater 
negative outcomes of maternal distress in female offspring in early childhood.
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Abstract
Maternal emotional distress symptoms, including life satisfaction, anxiety and depressed 
mood, are worse in Severely Obese (SO) than lean pregnancy and may alter placental genes 
regulating fetal glucocorticoid exposure and placental growth. We hypothesised that the 
associations between increased maternal distress symptoms and changes in placental gene
expression including IGF2 and genes regulating fetal glucocorticoid exposure are more 
pronounced in SO pregnancy. We also considered whether there were sex-specific effects.
Placental mRNA levels of 11-HSDs, NR3C1-, NR3C2, ABC transporters, mTOR and the 
IGF2 family were measured in term placental samples from 43 lean (BMI ≤25 kg/m2) and 50 
SO (BMI ≥40 kg/m2) women, in whom distress symptoms were prospectively evaluated
during pregnancy. The mRNA levels of genes with a similar role in regulating fetal 
glucocorticoid exposure were strongly inter-correlated. Increased maternal distress symptoms 
associated with increased NR3C2 and IGF2 isoform 1(IGF2-1) in both lean and SO group 
(p≤ 0.05). Increased distress was associated with higher ABCB1 and ABCG2 mRNA levels 
in SO but lower ABCB1 and higher 11-HSD1 mRNA levels in lean (p≤ 0.05) suggesting a 
protective adaptive response in SO placentas. Increased maternal distress associated with 
reduced mRNA levels of ABCB1, ABCG2, 11-HSD2, NR3C1-and IGF2-1 in placentas of 
female but not male offspring. The observed sex differences in placental responses suggest 
greater vulnerability of female fetuses to maternal distress with potentially greater fetal 
glucocorticoid exposure and excess IGF2. Further studies are needed to replicate these 
findings and to test whether this translates to potentially greater negative outcomes of 
maternal distress in female offspring in early childhood.
Key Words
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obesity, pregnancy, anxiety, depression, life satisfaction, placenta, glucocorticoids, ABC 
transporters, 11b-dehydrogenase, IGF2 
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1. Introduction
Obesity and emotional distress symptoms such as anxiety and depression (A&D) are 
prevalent during pregnancy (Gavin et al., 2005, Heslehurst et al., 2010). Both independently 
associate with increased obstetric complications, adverse birth outcomes (Alder et al., 2007) 
postpartum depression (Molyneaux et al., 2014), and also poor infant health (Lawlor et al.,
2012), cognitive and behavioural development (Van Lieshout et al., 2011).
One of the key pathways linking maternal obesity and A&D with adverse pregnancy 
outcomes is altered maternal hypothalamic-pituitary-adrenal (HPA) axis activity (Lopresti & 
Drummond, 2013). Increased glucocorticoid exposure during pregnancy in association with
maternal A&D has been associated with cognitive and behavioural problems (Mina & 
Reynolds, 2014). It is also strongly linked to low birth weight, leading to increased metabolic 
and cardiovascular risk in later life (Reynolds, 2013). We previously demonstrated that 
maternal very severe obesity (SO, WHO obese class III, BMI ≥ 40 kg/m2) is independently 
associated with antenatal A&D symptoms (Mina et al., 2015), emphasising the importance of 
co-investigating both conditions to further understand their adverse impact on fetal outcome 
and future infant health.
Changes in the maternal HPA axis during gestation promote increased glucocorticoids
(Mastorakos and Ilias, 2003), which are important for fetal lung maturation. The placenta 
modulates fetal glucocorticoid exposure, but is also developmentally plastic and is therefore 
responsive to insults. The fetus is protected from excess maternal cortisol by placental 11 
beta-hydroxysteroid dehydrogenase (11-HSD) 2 (Chapman et al., 2013), and down 
regulation of 11-HSD2 has been associated with increased maternal anxiety (O’Donnell et 
al., 2012) but not depression (Ponder et al., 2011, O’Donnell et al., 2012, Reynolds et al.,
2015). No studies have linked maternal A&D to placental 11-HSD1 (Reynolds et al., 2015), 
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which catalyses the regeneration of active glucocorticoids. We recently showed that maternal 
depressive symptoms associate with increased mRNA levels of placental glucocorticoid 
receptor (NR3C1) and mineralocorticoid receptor (NR3C2) (Reynolds et al., 2015). This, and 
the observation of links between maternal A&D and altered methylation of placental NR3C1
(Conradt et al., 2013), implies altered placental sensitivity to glucocorticoids in association 
with maternal A&D. A further level of control of fetal glucocorticoid exposure is through 
retrograde transfer of glucocorticoids from placenta to mother via the placental ATP- Binding 
Cassette (ABC) transporter family (apical ABCB1 and ABCG2, basal ABCC1). Whether 
mRNA levels of these transporters are associated with maternal A&D has not been 
investigated.
In animal models maternal prenatal stress also increases expression of placental 
Insulin- like Growth Factor (IGF) 2 (Pankevich et al., 2009), a key factor regulating placental 
and fetal growth and development (Burton and Fowden, 2012). Placental IGF2 expression is 
also vulnerable to maternal obesity, though varies with gestation. For example, increased 
mRNA levels of igf2 at day 16 of pregnancy were observed in placentas from the fetuses of 
dams fed with high-fat diet during pregnancy as compared to dams with standard diet, 
although this effect was no longer observed at day 19 of pregnancy (Sferuzzi-ferri et al.,
2013). Preliminary data suggests that igf2 mRNA levels are modulated by prevailing 
glucocorticoid levels (Vaughan et al., 2012) and may be sex-specific with up-regulation of
placental igf2 transcription by glucocorticoids in placentas of male, but not in female mice 
offspring (Cuffe et al., 2012). Mammalian Target of Rapamycin (mTOR), an intracellular 
nutrient stress sensor in the placenta (Roos et al., 2009) has been linked to the downstream 
signalling of both glucocorticoids (Jellyman et al., 2012) and IGF2 (Dai et al., 2011). A small 
study reporting a lower placental DEP domain-containing mTOR-interacting protein
(DEPTOR) in mothers with higher perceived life stress and reduced DEPTOR following 
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increased cortisol in vitro (Mparmpakas et al., 2012) suggests further investigation of these 
genes is warranted.
In this study, we aimed to evaluate the effects of both maternal obesity and A&D 
symptoms on placental mRNA levels of genes regulating fetal glucocorticoid exposure and 
the IGF2 family. We hypothesised that increased maternal emotional distress symptoms 
would be associated with changes in placental gene expression leading to a reduced placental 
barrier to excess maternal glucocorticoid levels and increased IGF2 mRNA levels. We 
speculated that this would be more pronounced in maternal obesity due to the greater levels 
of distress symptoms compared to lean (Mina et al., 2015). We considered whether there 
were sex- specific changes in placental gene expression in association with maternal distress.
To test this hypothesis we used placental samples collected at term from SO women and lean 
controls participating in a longitudinal case-control study of obesity in pregnancy and in 
whom maternal A&D symptoms and serum cortisol levels were assessed prospectively
during pregnancy (Mina et al., 2015).
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2. Materials and Methods
2.1. Participants
This study included women with singleton pregnancies participating in a prospective case-
control study comparing lean (BMI ≤25 kg/m2) and SO (BMI ≥40 kg/m2) women in 
Edinburgh, Scotland, UK. As previously described, SO women were recruited from a 
specialist antenatal metabolic clinic for women with BMI>40 kg/m2) whilst lean women were 
recruited from community antenatal clinics (Mina et al., 2015). Maternal body composition, 
maternal and pregnancy factors were characterised (Mina et al., 2015). All samples and data 
were collected with ethical approval (references 08/S1101/39 and 13/ES/0126), and with 
fully informed and written consent from all women.
2.2. Assessments of emotional distress and measurement of serum cortisol
Maternal distress was assessed at week 17 and at week 28 of gestation (Mina et al., 2015).
Briefly, the assessment comprised 5 previously validated self-rating items in printed 
questionnaires: 1) psychosocial risk factor assessment (Rosengren et al., 2004); 2) 
Satisfaction with Life Scale (SWLS, Diener et al., 1985); 3) General Health Questionnaire 
(GHQ, Goldberg 1972); 4) Hospital Anxiety and Depression Scale (HADS, Zigmond & 
Snaith 1983) and 5) State-Trait Anxiety Index (STAI, Spielberger 1927). A single question
“Have you consulted your General Practitioner (GP) about mental health issues in the last 2 
years?” was included.
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Serum cortisol levels were measured in maternal samples collected at 9am in the morning 
following an overnight fast during the first clinic visit (week 17), week 28 and 36 of 
pregnancy, as previously described (Stirrat et al., 2014, Mina et al., 2015).
2.3. Placental tissue collection, RNA extraction and quality assessment
Placental tissues were taken as single biopsies from the maternal side of the placenta and 
were stored in RNAlater solution (Qiagen, Manchester, UK) at 4˚C for 24 hours and 
subsequently frozen at -80˚C. A set of 93 placental samples (43 lean and 50 SO) were 
randomly selected after excluding samples from participants with gestational diabetes 
mellitus, treated with antenatal steroids during pregnancy and preterm births. For RNA 
extraction, approximately 30 mg of frozen placental tissues was excised and snap-frozen into 
Magnalyser green beads (Roche, Burgess Hill, UK). Each sample was subsequently 
submerged in 500 l buffer RLT (part of Qiagen RNeasy Fibrous Tissue Mini kit) with 
additional -mercaptoethanol (10:1), then homogenised with Qiagen Tissue Lyser for 50 
seconds x 25 Hz for 4-5 times with brief ice interruption to keep the Magnalyser tubes cool. 
Following tissue lysis, lysates were processed as per the Qiagen RNeasy Fibrous Tissue Mini 
kit protocol. RNA concentration was quantified by Nanodrop (Thermo-Scientific, 
Loughborough, UK). RNA integrity was evaluated by Agilent 6000 Nano eukaryotic total 
RNA assay (Agilent, Berkshire, UK).
2.4. Primer design and validation, cDNA synthesis and Quantitative Real Time PCR 
(QRTPCR)
Placental cDNA was synthesised with ABI High Capacity Reverse Transcriptase kit (Life 
Technologies, Paisley, UK) as per the manufacturer’s instruction into 500 ng/l end-product.
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Exon-exon junction spanning- primers and probe pairs for FAM hydrolysis were 
designed using ProbeFinder v2.50 for ABCB1, ABCC1, ABCG2, 11-HSD1, 11-HSD2, 
NR3C1-, NR3C2, IGF2 isoform 1(IGF2-1), IGF2 isoform 2 (IGF2-2), IGF2 receptor 
(IGF2R), and mTOR (Roche, A Table 1). Primers were validated in silico with 
PrimerBLAST (NCBI) and in vivo with conventional PCR using reagents and protocol from 
GoTaq®2 DNA polymerase mixture (Promega, Southampton, UK). The conventional PCR 
product was run in 2% agarose gel with 1X gel-red (Biotium, Cambridge, UK) along with 
100-bp DNA ladder (TrackitTM, Invitrogen, Life Technologies) in 0.5x TBE buffer to assess 
probe specificity.
For absolute QRTPCR, all samples were assayed in triplicates using FAM hydrolysis 
thermal cycling set-up in LightCycler 480 QRTPCR system (Roche), and housekeeping 
genes assay was performed for each batch of cDNA synthesis. A standard curve was prepared
by pooling 1μl of each cDNA sample, which was diluted 1:4 with RNase-free water, and then 
serially diluted 1:2 to produce 8 standards (1:4- 1:512). The QRTPCR reaction mixture was 
prepared following PerfeCTa® QRTPCR Fastmix® II (Quanta Biosciences, VWR, 
Leicestershire, UK) protocol, with final primer concentration = 250 nM, probe = 100 nM and 
cDNA per reaction = 25 ng. The datasets were analysed with LightCycler 480 QRTPCR 
software using E-Methods, and only those with standard error ≤0.05 and efficiency ≥1.7 were 
considered for further analysis (A Table 2). Two housekeeping genes suitable for placental 
tissue (YWHAZ and TBP, Meller et al., 2005) were utilised.
2.5. Covariates, Confounders and Moderators
Age, parity, deprivation category, alcohol and cigarette consumption before pregnancy, use 
of anti-depressants, history of polycystic ovarian syndrome (PCOS), inflammatory illnesses, 
and minor obstetric complications were assessed by questionnaire and verified through search 
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of hospital records. Delivery outcomes such as birth weight, mode of delivery, fetal sex, and 
gestational age were extracted from hospital records.
2.6. Statistical Analyses
Statistical analyses were performed using SPSS 19 (IBM, New York, USA). P≤0.05 was used 
as a cut-off of statistical significance. Prior to any analyses, data distribution was determined 
by Q-Q Plot and by histogram visualisation. The gene expression data were first normalised 
using an average of YWHAZ and TBP housekeeping genes and then log-transformed. For the 
distress questionnaires there were missing data due to either improper completion of the 
questionnaire or failure to complete an entire scale. Overall there were 2.3 % missing distress
assessment data in lean and 12% in the SO group. Missing data imputation was performed on 
these data using Markov Chain Monte Carlo (MCMC) algorithm.
Pearson’s correlations were used to test intra- and inter-correlation among the genes. 
Any non-linear correlations were detected using curve-fitting method. To avoid multiple 
statistical testing when interpreting the A&D questionnaire data, we restricted our analysis to 
include ‘state anxiety’ (as this differed between SO and lean) and used the averaged z-scores 
of either “anxiety symptoms” (Hospital Anxiety (HA) from HADS, State and Trait Anxiety) 
or “depression symptoms” (Hospital Depression (HD) from HADS and GHQ) (as in Mina et 
al., 2015). Serum cortisol level at week 36 pregnancy was selected as it was the nearest to the 
delivery. 
Due to the large numbers of variables examined, a set of covariates and confounders 
was constructed for each of the lean, SO, male and female placental pool by testing the 
correlations of the genes with variables which either differed between SO and lean groups
(Mina et al., 2015), or have been shown to greatly influence placental gene expression
(Burton and Fowden 2012, Burton et al., 2014, Räikkönen et al 2014, Reynolds et al., 2015)
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(A Table 3). We also tested whether fetal sex was a potential confounder for lean and SO 
pool, and vice versa (A Table 3). Multiple linear regressions with step-down methods were 
subsequently applied to assess whether maternal emotional distress symptoms were 
associated with gene mRNA levels in the SO group and separately in the lean group. We then 
repeated the analyses in the male and female offspring, respectively.
Power calculation was performed using GPower 3.1 with command [F-Test, Linear 
Multiple Regression: Fixed model, R2 increase, a priori mode]. We used 70% and 90% as 
minimum and maximum power, respectively, with  = 0.05. Mood symptoms at week 17 
were taken as reference. Random integer generator (http://www.random.org/integers/) was 
used to determine 2 representative genes, and where applicable comprised both significant 
and not significant associations. Analyses were performed in each BMI group and fetal sex
group. The power for all maternal SO and fetal sex analyses was >90%, except for the 
associations involving anxiety symptoms in male group (<70%).
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3. Results
3.1. The demographics of participants
Table 1 presents the demographics of participants (lean n= 43, SO n= 50) and the details of 
delivery mode and birth outcomes. SO group had higher maternal emotional distress
symptoms and lower serum cortisol levels as compared to the lean women, consistent with 
the cohort’s findings (Mina et al., 2015). There were significantly higher numbers of
caesarean deliveries in SO group as compared to lean. In this randomly selected sample there 
was a significant difference in the sex composition with more males from SO women. 
3.2. Correlations among glucocorticoid-linked genes and IGF2 family
Table 2 presents the inter-correlation of mRNA levels among the placental genes. The genes
which either facilitate (ABCC1, 11HSD1) or prevent (ABCB1, ABCG2, 11HSD2) fetal
glucocorticoid exposure were positively correlated. The mRNA levels of the glucocorticoid
receptor NRC31- were positively correlated with genes facilitating fetal glucocorticoid
exposure, but negatively correlated with genes preventing fetal glucocorticoid exposure.
IGF2 isoforms, IGFR and mTOR were positively correlated. IGF2-2 isoform was not 
transcribed as much as IGF2-1 isoform (A Fig 1), consistent with previous findings (De 
Ceuninck et al., 1995).The mRNA levels of the IGF2 family and mTOR were also positively 
correlated with genes facilitating fetal glucocorticoid exposure (NR3C1-, ABCG2), 
negatively correlated with ABCB1, and not with 11-HSD2. The mRNA levels of NR3C2 
did not correlate with any of the studied genes (Table 2).
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In unadjusted analyses there were no significant linear associations between cortisol 
levels and mRNA levels of the tested genes. However, after adjustment for confounders
including maternal age, antidepressant use during pregnancy, fetal sex and deprivation 
category, lower serum cortisol level at week 36 pregnancy was associated with increased
NR3C2 mRNA levels in the SO group (=-0.42, p= 0.03), while increased serum cortisol 
level was associated with increased ABCC1 mRNA levels in the lean group (=0.37, 
p=0.017). There was an inverted U-shaped correlation between 11-HSD2 mRNA levels and 
serum cortisol levels in total sample pool such that 11-HSD2 levels were lowest at both low 
and high cortisol levels (R= 0.11, p = 0.03, A Fig 2). Although there were no differences in 
serum cortisol levels according to fetal sex, some sex-specific associations between serum 
cortisol and placental mRNA levels were observed. In placentas with female fetuses, 
increased serum cortisol level was associated with higher ABCC1 (= 0.52, p≤ 0.05), 11-
HSD1 ((= 0.46, p≤ 0.05) and IGF2-1 (=0.35, p≤ 0.05) mRNA levels. In placentas with 
male fetuses, increased serum cortisol was associated with lower 11-HSD1 (=-0.48, p≤ 
0.05) and NR3C1- (= -0.32, p≤ 0.05) mRNA levels. 
3.3. Placental glucocorticoid-linked and IGF2 family mRNA levels associate with 
maternal emotional distress symptoms in both obese and lean
In the total sample pool regardless of maternal obesity status, increased maternal distress at 
week 28 pregnancy was correlated increased mRNA levels of IGF2-1 (r=p≤0.01 with 
reduced SWLS) and reduced IGF2-2 (r=with anxiety symptoms and r= with 
depression symptomsall p≤0.05). There were no differences in the mRNA levels of any of 
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the genes tested according to maternal obesity status except for lower ABCB1 mRNA levels 
in SO compared to lean in adjusted analyses (= p0.019).
In the SO group, lower perceived life satisfaction (higher emotional distress) at week 
17 of pregnancy was associated with higher ABCG2 (= -0.46, p≤ 0.05) and with higher 
NR3C2 (Fig 1A) mRNA levels. Lower life satisfaction at week 28 pregnancy in SO group 
was also associated with higher IGF2-1 gene expression (Fig 1B). A similar pattern was 
observed in the lean group where increased state anxiety at week 17 pregnancy (higher 
emotional distress) was associated with higher mRNA levels of NR3C2 (Fig 1A) and IGF2-1 
(Fig 1B).
In the SO group, lower perceived life satisfaction at week 17 pregnancy was 
associated with higher ABCB1 (Fig 1C). In contrast in lean, lower life satisfaction in early 
(week 17) and late (week 28) pregnancy was associated with decreased ABCB1 mRNA 
levels (Fig 1C and = 0.34, p≤ 0.05, respectively). Furthermore, increased anxiety symptoms 
at week 17 pregnancy were associated with increased 11-HSD1 mRNA levels (= 0.35, p≤ 
0.05) in lean, but not in the SO group.
There were no associations of maternal A&D symptoms or satisfaction with life with 
the mRNA levels of 11-HSD2, NR3C1-, IGF2-2, IGF2R and mTOR in either group.
3.4. The changes of glucocorticoid-linked and IGF2 family placental genes with 
increased maternal emotional distress symptoms are sex-specific
Regardless of maternal SO status, the mRNA levels of some placental genes differed 
significantly according to fetal sex (NR3C1 [p<0.001], NR3C2 [p= 0.05], IGF2-2 [p= 0.05], 
IGF2-R [p= 0.02] were all higher in females). Fetal sex also emerged as an important 
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confounder for some genes during the obesity-based analyses. Analysing the data separately 
for males and females revealed sex differences in the associations between placental gene 
expression and maternal emotional distress symptoms (Table 3). In pregnancies with female 
fetuses, mRNA levels of genes which prevent glucocorticoid transfer to the fetuses were 
lower (ABCB1, ABCG2, 11HSD2, Table 3) in women with increased emotional distress 
symptoms (increased A&D symptoms or decreased SWLS). In female placentas the mRNA 
levels of NR3C1- were also higher in association with lower perceived life satisfaction
(higher emotional distress) (Table 3). In contrast, in male placentas, lower perceived life 
satisfaction was associated with increased mRNA levels of genes which prevent 
glucocorticoid transfer to the fetuses (ABCG2, 11HSD2, Table 3), suggesting a protective 
effect. After additional adjustment for serum cortisol level at week 36 pregnancy, reduced life 
satisfaction was also associated with increased 11HSD1 in males (=-0.39, p≤ 0.05).
Table 3 also demonstrates that increased maternal emotional distress symptoms were 
associated with increased IGF2-1 and with trends for increased IGF2R mRNA levels in 
female, but not in male placentas. In male placentas, increased state anxiety in week 17 was 
associated with reduced IGF2-2 mRNA level (= -0.45, p ≤0.05). The associations involving 
IGF2-1 in female placentas were no longer significant when adjusted for serum cortisol level 
at week 36 pregnancy. No significant associations were found in ABCC1, NR3C2, mTOR 
mRNA levels with maternal A&D symptoms in either sex. Overall, Table 3 suggests that 
female placentas were more responsive to increased maternal emotional distress symptoms.
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4. Discussion
Our findings demonstrate that maternal emotional distress associates with changes in mRNA 
levels of several placental genes involved in the regulation of fetal glucocorticoid exposure 
and placental growth. Contrary to our hypothesis we found that the pattern of changes in 
mRNA levels in placentas from SO women (who had greater A&D symptoms than lean), 
were largely similar to those in placentas from lean women. However, in exploratory 
analyses we observed sex-specific responses, with placentas with female fetuses appearing 
more vulnerable to maternal A&D symptoms than placentas with males. 
To our knowledge, no other studies using human placentas have investigated whether 
mRNA levels of glucocorticoid-linked or the IGF2 family genes vary according to maternal 
obesity. Despite marked differences in obesity levels between our study groups, only the 
mRNA levels of ABCB1 significantly differed, with lower levels in placentas from SO than 
lean women. The physiological relevance of this observation is not known as placental 
ABCB1 levels are lowest at late stages of pregnancy (Sun et al 2006), but as ABCB1 actively 
pumps various xenobiotics and glucocorticoids from the fetal to the maternal circulation
(Kalabis et al., 2005), the lower ABCB1 levels in SO may partly explain the lower maternal 
circulating cortisol levels. Although there are no studies in placenta, global deficiency of 
ABCB1 appears to be associated with susceptibility to developing obesity in rodent models,
since feeding Pgp (abcb1) knock-out mice with a high-fat diet induced obesity (Foucaud-
Vignault et al., 2011). Likewise, in humans, a polymorphism of ABCB1 influencing 
transcription and function is associated with obesity (Ichihara et al., 2008). Whether there is a 
genetic susceptibility to decreased ABCB1 activity in this cohort of SO women is unknown. 
Notably, the observations of increased placental igf2, nr3c1 and igf2r in rodent models 
receiving either an obesogenic diet during pregnancy (Sferuzzi-ferri et al., 2013) or a chronic 
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obesogenic diet (King et al 2013) were restricted to mid-gestation with no differences at term. 
If there are similar transient changes in mRNA levels in mid gestation in human placenta, this 
may explain the lack of differences between lean and SO in our study using samples collected 
at term.
The pattern of changes in placental mRNA levels, other than ABCB1, with maternal 
distress was similar in lean and SO. For example, increased maternal emotional distress, as 
reported by increased state anxiety scores or reduced scores on the SWLS, was associated 
with increased mRNA levels of NR3C2 and IGF2-1 in both groups. This is similar to the 
increased placental mRNA levels of NR3C2 in association with maternal depressive 
symptoms in another cohort of pregnant women (Reynolds et al., 2015), a finding consistent 
with increased placental sensitivity to glucocorticoids in situations of maternal distress. The 
IGF2-1 findings are novel but differ from a study reporting no significant associations 
between IGF2 DNA methylation and diagnosis of maternal depression in pregnancy (Liu et 
al., 2012). This discrepancy may be due to our focus on a spectrum of maternal emotional 
distress symptoms rather than a clinical diagnosis of a psychiatric disorder. We also observed 
increased 11HSD1 mRNA level following increased state anxiety in lean, a similar finding
to that observed in mothers with lower socio-economic status (Raikkonen et al., 2014), 
another strong indicator of maternal wellbeing (Heslehurst et al., 2010). This is in accord 
with literature supporting increased fetal glucocorticoid exposure with increased maternal 
distress during pregnancy (Duthie and Reynolds, 2013). Indeed, the placental glucocorticoid 
barrier in lean seems more sensitive to maternal distress as lower maternal distress in lean 
placentas was also associated with lower ABCB1 mRNA levels, implying more retrograde 
transfer of glucocorticoids back to the maternal circulation. Furthermore, contrary to our 
hypothesis, our data also suggest a paradoxically improved placental glucocorticoid barrier 
following increased maternal distress in SO placentas since first, the mRNA levels of 11-
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HSD1 in SO group remained unaltered unlike in lean, and second the ABCB1 and ABCG2
mRNA levels, both of which transport glucocorticoids from fetus to mother, were higher 
following reduced life satisfaction.
The marked differences in gene expression according to fetal sex suggest that sex 
dimorphism modulates placental responses to maternal A&D symptoms at the transcriptional 
level. We acknowledge that these findings need to be interpreted with caution, particularly as
there was a difference in sex composition of the placental samples obtained from SO and lean 
women, but the observed changes in gene expression according to fetal sex remained 
significant after adjustment for maternal obesity. Human studies investigating the impact of 
maternal A&D on gene expression and/or epigenetic changes of glucocorticoid-linked genes 
in placenta and cord blood have either adjusted for sex or have not reported any sex
difference (Oberlander et al., 2008, Ponder et al., 2011, O’Donnell et al., 2012, Raikkonen et 
al., 2014; Reynolds et al., 2015). Only one study highlighted the lower methylation of IGF2 
in low birth weight female infants from mothers with depression (Liu et al., 2012), and 
accordingly we observed higher mRNA levels of IGF2-1 in placentas from females in 
association with increased maternal A&D symptoms. Further studies are needed to replicate 
these findings and follow-up of this cohort is needed to test whether these findings will 
translate into sexual dimorphism of stress reactivity (Davis & Emory, 1995) or behaviours 
(Connellan et al., 2000) in infant and childhood.
Given the pivotal role of placental 11-HSD2 in regulating fetal glucocorticoid 
exposure, we were surprised that it did not associate with maternal obesity, A&D symptoms 
or serum cortisol level. A previous study which showed associations between maternal 
anxiety and down-regulation of 11-HSD2 (O’Donnell et al 2012), included assessment of 
maternal mood on the day before caesarean delivery, which may have influenced the state 
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anxiety responses to the questionnaire, whereas we evaluated mood symptoms prospectively. 
We previously reported non-linear correlations between maternal anxiety and serum cortisol 
level across pregnancy (Mina et al., 2015) and the non-linear correlation of serum cortisol 
with 11-HSD2 observed here may have masked any findings. In addition, the existing 
literature in this field is conflicting since synthetic glucocorticoids have been reported to
increase 11-HSD2 abundance (van Beek et al., 2004) whilst increasing endogenous cortisol 
at time of labour associated with decreased 11-HSD2 abundance (Murphy and Clifton,
2003).
Importantly our study demonstrated that the prevailing level of circulating cortisol in 
late pregnancy may influence placental mRNA levels. For example, the associations of 
cortisol levels with the mRNA levels of 11-HSD1 in m le placentas and with ABCC1 and 
11-HSD1 in female, are in line with increased glucocorticoid transport to the fetus following 
increased maternal distress. The changes in the significance of the associations between
IGF2-1 mRNA level and maternal distress in female pool after adjusting for serum cortisol 
level also suggest that glucocorticoids are one of the factors mediating the impact of maternal 
distress on placental gene expression. Further studies are needed to explore this further, to 
examine cortisol measurements nearer the time of delivery and/or measurements of cortisol in 
cord blood, and to examine the role of other potential biological agents, such as inflammatory 
cytokines. 
The main strength of our study is the prospective study design and the well-defined 
case-control cohort with detailed characterisation in pregnancy, enabling us to adjust for an 
array of confounders. The subset of random samples that were selected for analysis were 
representative of the larger cohort (Mina et al., 2015) but were not complicated by cases of 
pre-term birth, antenatal steroids and gestational diabetes. We comprehensively assessed 
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placental genes regulating fetal glucocorticoid exposure including not only genes regulating 
glucocorticoid clearance and activation, but also genes involved in glucocorticoid sensitivity 
and transport across the placenta. Notably we found correlations among glucocorticoid-
linked and IGF2 gene family according to whether they facilitate or prevent fetal 
glucocorticoid exposure, suggesting synergistic regulation of the placental glucocorticoid 
barrier. We found no changes in the transcriptional level of mTOR by maternal obesity, A&D 
symptoms or fetal sex. Increased activation of mTOR complex has been correlated with cases 
of macrosomia in obese pregnancy (Jannsson et al., 2013) and further work should consider 
the mTOR signalling pathway
A limitation of our study is the lack of protein and/or enzyme activity data, and that
our work in term placenta could inevitably only provide a snapshot of events at the end of 
pregnancy at the only time the tissue can be collected. We also could not adjust for fetal 
cortisol levels in our analyses as cord blood and/or amniotic fluid samples were unavailable. 
However, we included adjustment for maternal serum cortisol level at week 36 pregnancy as 
it was the sample collected nearest to the time of delivery, and since maternal plasma cortisol 
levels are significantly correlated with cord plasma cortisol levels (Sybulski et al., 1975). The 
lower cortisol levels in our SO women were consistent with findings in overweight women 
(Wright et al., 2013) but further studies with more detailed assessment of cortisol during 
pregnancy and peripartum are needed. Of note, the inclusion of adjustment for maternal 
cortisol did impact on some of the findings. This is in accord with the changes in the mRNA 
levels of ABCB1, 11-HSD2 and NR3C1- following the modulation of serum 
glucocorticoids in healthy rat (Mark et al., 2009), mice (Cuffe et al., 2012) and in human 
placentas taken from women receiving antenatal steroids with small-for-gestational-age 
infants (Hodyl et al., 2013). Finally we acknowledge that the sex composition of the 
placentas in the SO group is significantly different from the controls and while we adjusted 
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for maternal obesity in the statistical analysis, the sex differences we observed require 
replication.
In conclusion, we observed changes in placental genes regulating fetal glucocorticoid
exposure and IGF2 in association with maternal emotional distress symptoms during 
pregnancy. The pattern of changes suggest placentas from lean are sensitive to maternal 
distress while there is a protective adaptive response in the placentas from SO. In addition, 
the observed sex differences in responses are consistent with potentially greater fetal 
glucocorticoid exposure and excess IGF2 in female fetuses following increased maternal 
A&D symptoms, suggesting greater vulnerability of females to maternal mood. Further 
studies are needed to replicate these findings and to test whether this translates to potentially 
greater negative outcomes of maternal A&D symptoms in females in early childhood.
Page 23 of 30
Ac
ce
pte
d M
an
us
cri
pt
Mina et al, 2015
23
References
Alder J, Fink N, Bitzer J, Hösli I, Holzgreve W., 2007. Depression and Anxiety during Pregnancy: A Risk Factor for 
Obstetric, Fetal and Neonatal Outcome? A Critical Review of the Literature. J. Matern. Neonatal. Med. 20(3), 189–
209.
Burton G, and Fowden A., 2012. The Placenta and Developmental Programming: Balancing Fetal Nutrient Demands with 
Maternal Resource Allocation. Placenta. 26 (33), S23–S27.
Burton G, Sebire N, Myatt L, Tannetta D, Wang Y-L, Sadovsky Y, Staff A, Redman C., 2014. Optimising Sample 
Collection for Placental Research. Placenta. 35(1), 9-22.
Chapman K, Holmes M, Seckl J., 2013. 11Β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue 
Glucocorticoid Action. Physiol. Rev. 93 (3), 1139–206.
Connellan J, Baron-Cohen S, Wheelwright S, Batki A, Ahluwalia J., 2000. Sex Differences in Human Neonatal Social 
Perception. Infant Behav. Dev. 23(1), 113–118.
Conradt E, Lester B, Appleton A, Armstrong D, Carmen J., 2013. The Roles of DNA Methylation of NR3C1 and 11β-HSD2 
and Exposure to Maternal Mood Disorder In Utero on Newborn Neurobehavior. Epigenetics. 8(12), 1321–1329.
Cuffe, J, O'Sullivan L, Simmons D, Anderson S, Moritz K., 2012. Maternal Corticosterone Exposure in the Mouse Has Sex-
Specific Effects on Placental Growth and mRNA Expression. Endocrinology. 153(11), 5500–5511.
Dai N, Rapley J, Angel M, Yanik M, Blower M, Avruch J., 2011. mTOR Phosphorylates IMP2 to Promote IGF2 mRNA 
Translation by Internal Ribosomal Entry. Genes Dev. 25(11), 1159–1172.
Davis M & Emory E., 1995. Sex Differences in Neonatal Stress Reactivity. Child Dev. 66(1), 14–27.
De Ceuninck F, Willeput J and Coryol M., 1995. Purification and characterization of insulin-like growth factor II (IGF II) 
and an IGF II variant from human placenta. J. Chromatogr. B. Biomed. Appl. 666(2), 203–214.Diener E, Emmons 
R, Larsen R, Griffin S., 1985. The Satisfaction with Life Scale. J. Personal. Assessment 49(1), 71–75. 
Duthie L & Reynolds R., 2013. Changes in the maternal hypothalamic-pituitary-adrenal axis in pregnancy and postpartum: 
influences on maternal and fetal outcomes. Neuroendocrinol. 98(2), 106–115.
Foucaud-Vignault M, Soayfane Z, Ménez C, Bertrand-Michel J, Martin P, Guillou H, Collet X, Lespine A., 2011. P-
glycoprotein Dysfunction Contributes to Hepatic Steatosis and Obesity in Mice. PloS One. 6(9), e23614.
Gavin N, Gaynes B, Lohr K, Meltzer-brody S, Gartlehner G, Swinson T., 2005. A Systematic Review of Prevalence and 
Incidence. Obstet. Gynecol. 106(5), 1071–1083.
Goldberg D., 1972. The Detection of Psychiatric Illness by Questionnaire. Oxford University Press, London.
Heslehurst N, Rankin J, Wilkinson J, Summerbell C., 2010. A Nationally Representative Study of Maternal Obesity in 
England, UK: Trends in Incidence and Demographic Inequalities in 619 323 Births, 1989-2007. Int. J Obes. 34(3), 
420–428.
Hodyl N, Stark M, Butler M, Clifton V, 2013. Placental P-glycoprotein Is Unaffected by Timing of Antenatal Glucocorticoid 
Therapy but Reduced in SGA Preterm Infants. Placenta. 34(4), 325–30.
Ichihara S, Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Kojima T, Watanabe S, Metoki N, Yoshida H, Satoh K, 
Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y., 2008. Association of a Polymorphism of ABCB1 with 
Obesity in Japanese Individuals. Genomics. 91(6), 512–516.
Page 24 of 30
Ac
ce
pte
d M
an
us
cri
pt
Mina et al, 2015
24
Jansson N, Aye I, Goberdhan D., 2013. Activation of Placental mTOR Signaling and Amino Acid Transporters in Obese 
Women Giving Birth to Large Babies. J. Clin. Endocrinol. Metab. 98(January 2013), 105–113.
Jellyman J, Martin-Gronert M, Cripps R, Giussani D, Ozanne S, Shen QW, Du M, Fowden A, Forhead A., 2012. Effects of 
Cortisol and Dexamethasone on Insulin Signalling Pathways in Skeletal Muscle of the Ovine Fetus during Late 
Gestation. PloS One. 7(12), e52363.
Kalabis G, Kostaki A, Andrews M, Petropoulos S, Gibb W, Matthews S., 2005. Multidrug Resistance Phosphoglycoprotein 
(ABCB1) in the Mouse Placenta: Fetal Protection. Biol. Reprod. 73(4), 591–597.
King V, Hibbert N, Seckl J, Norman J, Drake A., 2013. The Effects of an Obesogenic Diet during Pregnancy on Fetal 
Growth and Placental Gene Expression Are Gestation Dependent. Placenta. 34(11), 1087–1090.
Lawlor D, Relton C, Sattar N, Nelson S., 2012. Maternal Adiposity-A Determinant of Perinatal and Offspring Outcomes? 
Nat Rev Endocrinol. 8(11), 679–688.
Liu Y, Murphy S, Murtha A, Fuemmeler B, Schildkraut J, Overcash F, Kutzberg J, Jirtle R, Iversen E, Forman M, Hoyo C.,
2012. Depression in Pregnancy, Infant Birth Weight and DNA Methylation of Imprint Regulatory Elements. 
Epigenetics. 7(7), 735–746.
Lopresti A, Drummond P., 2013. Obesity and Psychiatric Disorders: Commonalities in Dysregulated Biological Pathways 
and Their Implications for Treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 92–99.
Mark P, Augustus S, Lewis J, Hewitt D, Waddell B., 2009. Changes in the Placental Glucocorticoid Barrier during Rat 
Pregnancy: Impact on Placental Corticosterone Levels and Regulation by Progesterone. Biol. Reprod. 80(6), 1209–
1215.
Mastorakos G, Ilias I., 2003. Maternal and Fetal Hypothalamic-Pituitary-Adrenal Axes During Pregnancy and Postpartum. 
Ann. N. Y. Acad. Sci. 997(1), 136–149.
Meller M, Vadackhoria S, Luthy D, Williams D., 2005. Evaluation of housekeeping genes in placental comparative 
expression studies. Placenta. 26(8-9), 601–607.
Mina T, Reynolds R., 2014. Mechanisms Linking In Utero Stress to Altered Offspring Behaviour. In: Bluhm MDL, Geyer 
M, Ellenbroek B, Marsden C. (Ed.), Curr. Top. Behav. Neurosci. Springerlink, Heidelberg, pp 93-122.
Mina et al., 2015. Associations of Mood Symptoms with Ante- and Postnatal Weight Change in Obese Pregnancy Are Not 
Mediated by Cortisol. Psychol. Med. (in press)
Molyneaux E, Poston L, Ashurst-Williams S, Howard L., 2014. Obesity and Mental Disorders During Pregnancy and 
Postpartum. Obstet. Gynecol. 123(4), 857–867.
Mparmpakas D, Zachariades E, Goumenu A, Gildron Y, Karteris E., 2012. Placental DEPTOR as a Stress Sensor during 
Pregnancy. Clin. Sci. 122, 349–359.
Murphy V & Clifton V., 2003. Alterations in Human Placental 11 -hydroxysteroid Dehydrogenase Type 1 and 2 with 
Gestational Age and Labour. Placenta. 24, 739–744.
O’Donnell K, Bugge Jensen A, Freeman L, Khalife N, O'Connor T, Glover V., 2012. Maternal prenatal anxiety and 
downregulation of placental 11β-HSD2. Psychoneuroendocrinology. 37(6), 818–826.
Oberlander T, Reebye P, Misri S, Papsdorf M, Kim J, Grunau R., 2008. Prenatal Exposure to Maternal Depression, Neonatal 
Methylation of Human Glucocorticoid Receptor Gene (NR3C1) and Infant Cortisol Stress Responses. Epigenetics. 3, 
97–106.
Pankevich D, Mueller B, Brockel B, Bale T., 2009. Prenatal Stress Programming of Offspring Feeding Behavior and Energy 
Balance Begins Early in Pregnancy. Physiol. Behav. 98(1-2), 94–102.
Ponder KL Salisbury A, McGonnigal B, Laliberte A, Lester B, Padbury J., 2011. Maternal Depression and Anxiety Are 
Associated with Altered Gene Expression in the Human Placenta without Modification by Antidepressant Use: 
Implications for Fetal Programming. Dev. Psychobiol. 53(7), 711–723.
Page 25 of 30
Ac
ce
pte
d M
an
us
cri
pt
Mina et al, 2015
25
Räikkönen K, O'reilly J, Pesonen A-K, Kajantie E, Villa P, Hämäläinen E, Seckl J, Reynolds R., 2014. Associations between 
Maternal Level of Education and Occupational Status with Placental Glucocorticoid Regeneration and Sensitivity.
Clin. Endocrinol. 81(2), 175–182.
Reynolds R., 2013. Glucocorticoid Eexcess and the Developmental Origins of Disease: Two Decades of Testing the 
Hypothesis--2012 Curt Richter Award Winner. Psychoneuroendocrinology. 38(1), 1–11.
Reynolds R, Pesonen A, O'Reilly J, Tuovinen S, Lahti M, Kajantie E, Villa P, Laivuori H, Hämäläinen E, Seckl J, 
Räikkönen K., 2015. Maternal Depressive Symptoms Throughout Pregnancy Are Associated with Incerased Placental 
Glucocorticoid Sensitivity, Psychol. Med., 28, 1-8.
Roos S, Powell T, & Jansson T., 2009. Placental mTOR Links Maternal Nutrient Availability to Fetal Growth. Biochem.
Soc. Transac. 37(Pt 1), 295–298.
Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed W, et al., 2004. Association of Psychosocial 4isk 
Factors with Risk of Acute Myocardial Infarction in 11119 Cases and 13648 Controls from 52 Countries (the 
INTERHEART Study): Case-Control Study. Lancet 364(9438), 953–962.
Sferruzzi-Perri A, Vaughan O, Haro M, Cooper W, Musial B, Charalambous M, Pestana D, Ayyar S, Ferguson-Smith A., 
2013. An Obesogenic Diet during Mouse Pregnancy Modifies Maternal Nutrient Partitioning and the Fetal Growth 
Trajectory. FASEB J. 27(10), 3928–3937.
Spielberger C., 1927. Manual for the State/Trait Anxiety Inventory (Form Y): (Self Evaluation Questionnaire). 1983rd ed. 
Consulting Psychologists Press, Palo Alto.
Stirrat L, O’Reilly J, Riley S, Howie A, Beckett G, Smith R, Walker B, Norman J, Reynolds R., 2014. Altered Maternal 
Hypothalamic-Pituitary-Adrenal Axis Activity in Obese Pregnancy Is Associated with Macrosomia and Prolonged 
Pregnancy. Pregnancy Hypertens. An. Int. J. Women’s Cardiovasc. Heal. 4(3), 238.
Sun M, Kingdom J, Baczyk D, Lye S, Matthews S, Gibb W., 2006. Expression of the Multidrug Resistance P-Glycoprotein, 
(ABCB1 glycoprotein) in the Human Placenta Decreases with Advancing Gestation. Placenta, 27(6-7), 602–609.
Sybulski S., Goldsmith WJ & Maughan GB., 1975. Cortisol Levels in Fetal Scalp, Maternal, and Umbilical Cord Plasma. 
Obstet Gynecol. 46(3), 268–271.
Van Beek J, Guan H, Julan L, Yang K., 2004. Glucocorticoids Stimulate the Expression of 11beta-Hydroxysteroid 
Dehydrogenase Type 2 in Cultured Human Placental Trophoblast Cells. J. Clin. Endo. Metab. 89(11), 5614–5621.
Van Lieshout R, Taylor V & Boyle M., 2011. Pre-Pregnancy and Pregnancy Obesity and Neurodevelopmental Outcomes in 
Offspring: A Systematic Review. Obes Rev. 12(5), e548–559.
Vaughan O, Sferuzzi-Perri A & Fowden A., 2012. Maternal Corticosterone Regulates Nutrient Allocation to Fetal Growth in 
Mice. J. Physiol. 590 (21), 5529-5540.
Wright R, Fisher K, Chiu Y, Wright R, Fein R, Cohen S, Coull B., 2013. Disrupted Prenatal Maternal Cortisol, Maternal 
Obesity, and Childhood Wheeze. Insights into Prenatal Programming.  Am. J. Respir. Crit. Care Med. 187 (11), 1186-
1193.
Zigmond A, Snaith R., 1983. The Hospital Anxiety and Depression Scale. Acta Physiol. Scand. 67, 361–370. 
Page 26 of 30
Ac
ce
pte
d M
an
us
cri
pt
Mina et al, 2015
26
Figure and Table Captions
Figure 1
Messenger RNA levels of glucocorticoid-related and IGF2-2 genes in the placenta 
according to maternal obesity. SO= Severely Obese. Life satisfaction refers to the SWLS 
scores (Satisfaction with Life Scale), in which the higher the score the better the wellbeing. 
For illustration purpose, both the X-axis of life satisfaction and the associated  values (R) 
were reversed. Y- Axis = log of normalised gene expressions against housekeeping genes. = 
adjusted for the list of confounders for lean and SO group respectively, as defined in S Table 
3. The mRNA levels of NR3C2 in SO group is additionally adjusted for serum cortisol level 
at week 36 of pregnancy. ∙∙∙∙∙∙95% confidence interval.
Table 1
The demographics of participants, SO= Severely Obese. Bold italic: p ≤ 0.05, underlined p 
≤ 0.1. a student’s t-test, b Fisher’s exact test, c Chi-square test. PCOS= Polycystic Ovarian 
Syndrome, HA= Hospital Anxiety, HD= Hospital Depression, GHQ= General Health 
Questionnaire. Averaged z-scores are derived from the z-scores of HA, State and Trait for 
anxiety symptoms and HD and GHQ only for depression symptoms. 1 Deprivation category 
was defined in Mcloone and Boody. 2 The definition of alcohol unit follows National Health 
Service (NHS) UK guideline. 3 Inflammatory symptoms were identified as actively having 
any of these conditions: eczema, rheumatoid arthritis, multiple sclerosis and Crohn’s disease. 
4 Minor obstetric complications include symphysis pubic dysfunction, chest infection, 
heartburn, headache, carpal tunnel syndrome, constipation, sciatica, hyperemesis and urinary 
tract infection.
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Table 2
Inter-correlation of mRNA levels of genes regulating fetal glucocorticoid exposure.
Correlation analysis was performed from log-transformed QPCR data. In bold, ***p ≤0.001, 
**p ≤0.01, *p ≤0.05, underlined p ≤0.1. Gc = glucocorticoids.
Table 3
The associations between the levels of placental GC- linked gene and IGF2 family gene 
expression and maternal mood symptoms are sex specific. Anx= averaged Z score from 
anxiety symptoms, Dep= averaged Z score, SWLS= Satisfaction with Life Scale. In bold, **p 
≤0.01, *p ≤0.05; underline: p ≤ 0.1, ns= not significant. Shadowed cells represent genes 
which prevent foetal GC exposures.  aThe results in female pool are prior to adjusting for 
cortisol level at week 36 pregnancy; adjusting for cortisol level did not affect the analyses 
involving ABCC1 and 11-HSD1 in female pool.
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Table 1
Demographics Lean (n = 43) SO (n = 50) p
BMI (kg/m2), mean (SD) 22.83 (1.55) 43.94 (3.71) ≤0.0001
Age, mean (SD) 33.96 (4.09) 31.48 (5.41) 0.016a
0 27 (62.79) 25 (50)
Parity, n (%)
≥1 16 (37.21) 25 (50)
0.295b
Affluent- intermediate 29 (67.44) 20 (40)
Deprivation category, n (%) 1
Deprived- very deprived 14 (32.56) 30 (60)
0.012b
Alcohol unit consumed before pregnancy, mean (SD) 2 7.4 (6.53) 4.09 (4.86) 0.017a
Smoking during pregnancy, n (%) 2 (4.65) 6 (12) 0.278b
Antidepressants, n (%) 2 (4.65) 2 (4) 1b
PCOS, n (%) 4 (9.30) 4 (8) 1b
Inflammatory symptoms, n (%) 3 9 (20.93) 14 (28) 0.473b
Minor obstetric complications, mean (SD) 4 2.9 (1.56) 3.39 (1.7) 0.165a
HA 5.67 (3.1) 6.1 (3.24) 0.517a
State 30.17 (7.47) 34.84 (9.54) 0.012a
Trait 34.14 (9.5) 36.55 (10.23) 0.25a
Anxiety symptoms
Averaged z-score -0.12 (0.87) 0.18 (0.96) 0.128a
Satisfaction with Life Scale (SWLS) 29.95 (6.19) 24.59 (5.27) 0.052a
HD 2.29 (2.06) 3.84 (2.76) 0.004a
GHQ 1.98 (2.07) 3.35 (2.5) 0.006aW
ee
k 
17
 p
re
gn
an
cy
Depression symptoms
Averaged z-score -0.24 (0.73) 0.23 (0.92) 0.002a
HA 5.67 (3.06) 6.68 (3.65) 0.157a
State 31.86 (9.2) 35.54 (11.01) 0.089a
Trait 33.9 (8.71) 37.42 (11.91) 0.116a
Anxiety symptoms
Averaged z-score -0.05(0.86) 0.31 (1.12) 0.092a
Satisfaction with Life Scale (SWLS) 27.67 (4.78) 25.04 (5.12) 0.013a
HD 2.26 (2.05) 4.36 (3.09) ≤0.0001a
GHQ 2.29 (2.11) 3.64 (3.20) 0.021aW
ee
k 
28
 p
re
gn
an
cy
Depression symptoms
Averaged z-score -0.32 (0.72) 0.33 (1.13) 0.002a
Week 17 pregnancy 3.14 (0.21) 2.97 (0.23) 0.001a
Week 28 pregnancy 3.29 (0.31) 3.13 (0.17) 0.006aLog plasma cortisol
Week 36 pregnancy 3.30 (0.16) 3.17 (0.20) 0.002a
Male 14 (32.56) 30 (60)
Baby gender, n (%)
Female 29 (67.44) 20 (40)
0.012b
Vaginal 27 (62.79) 14 (28)
Mode of delivery, n (%)
Caesarean 16 (37.21) 36 (72)
0.003c
Gestational age in days, mean (SD) 281.48 (9.69) 281.12 (9.18) 0.851a
Overall 3446.9 (434.3) 3554.6 (636.6) 0.351a
Male 3449.28 (361.9) 3708.33 (520.5) 0.101aBirth weight in grams, mean (SD)
Female 3445.75 (471.2) 3324 (733.7) 0.482a
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Table 2
Table 3
Male (n = 44) Female (n = 49)
week 17 week 28 week 17 week 28 (p)
Anx Dep SWLS Anx Dep SWLS Anx Dep SWLS Anx Dep SWLS
ABCB1 0.21 0.15 -0.24 0.16 0.04 -0.21 -0.20 -0.29 0.48 -0.28 -0.3* 0.55**
ABCC1 -0.29 -0.15 0.30 -0.20 0.03 -0.02 0.17 -0.01 0.32 -0.12 -0.16 0.00
ABCG2 0.11 0.15 -0.31 0.03 0.09 -0.35* -0.24 -0.37* 0.38 -0.27 -0.29* 0.29*
11-HSD1 -0.05 0.11 0.15 0.02 0.17 -0.39* 0.16 0.14 0.06 -0.10 -0.16 -0.01
11-HSD2 0.17 0.21 -0.44* 0.06 -0.16 -0.33 -0.08 -0.11 0.21 -0.20 -0.34* 0.43*
NR3C1- -0.01 -0.08 -0.24 -0.14 -0.02 0.07 0.06 0.16 -0.26 0.12 0.29 -0.32*
NR3C2 -0.03 0.02 -0.31 -0.18 -0.03 0.01 0.15 0.23 0.02 0.07 0.01 0.13
IGF2-1a 0.07 0.13 -0.05 -0.04 0.10 -0.20 0.14 0.27 -0.24 0.38** 0.4** -0.38*
IGF2-2 -0.25 -0.15 0.12 -0.24 -0.10 0.02 0.04 -0.10 0.07 -0.11 -0.03 0.03
IGF2R -0.04 0.00 -0.05 -0.13 -0.10 -0.10 0.19 0.43** -0.24 0.23 0.27 -0.26
mTOR -0.24 -0.18 0.16 -0.16 0.01 -0.02 0.13 -0.10 0.24 0.06 0.05 0.11
Gc Retrograde transfer Gc enzymatic clearance Gc sensitivity IGF2, receptor, downstream signalPearson's
Correlation ABCB1 ABCC1 ABCG2 HSD1 HSD2 NR3C1- NR3C2 IGF2_1 IGF2_2 IGF2R mTOR
ABCB1 1
ABCC1 0.0 1
ABCG2 0.5*** -0.0 1
HSD1 0. 0.7*** 0.0 1
HSD2 0.5*** -0.2* 0.4*** -0.1 1
NR3C1- 0.1 0.4*** 0.2* 0.4*** -0.2* 1
NR3C2 0.1 -0.0 0.2 0.1 0.1 0.2 1
IGF2-1 -0.0 0.4*** 0.3** 0.4*** -0.1 0.4*** 0.4*** 1
IGF2-2 0.1 0.6*** 0.1 0.4*** -0.1 0.2* 0.0 0.3*** 1
IGF2R -0.2* 0.3** -0.1 0.4*** -0.1 0.3** 0.1 0.3** 0.1 1
mTOR 0.3* 0.5*** 0.3** 0.4*** 0.0 0.2* 0.1 0.5*** 0.5*** 0.1 1
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